WordPress database error: [Table 'thehealthcarenews_org_db.wp_ppress_sessions' doesn't exist]
SELECT * FROM wp_ppress_sessions WHERE session_key = '333cfb96ffa56ac7d326f958cea4268d'

American Pharmaceutical and Biotech Company Moderna Inc Stock Outperforms Press "Enter" to skip to content

American Pharmaceutical and Biotech Company Moderna Inc Stock Outperforms

The Shares of Moderna Inc. inched 0.28% higher to $158.99 Tuesday. This proved to be an all-around dismal trading session for the Stock market, with the NASDAQ Composite Index COMP falling 0.09% to 13,389.43 and Dow Jones Industrial Average DJIA falling 1.36% to 34,269.16.

Moderna Inc. closed $30.27 below its 52-week high ($189.26), which the Company reached on February 8th. The stock outperformed some of its competitors Tuesday, as AbbVie Inc. ABBV fell 1.14% to $114.89, Amgen Inc. AMGN fell 0.13% to $252.30, and AstraZeneca PLC ADR AZN fell 0.51% to $54.10. Trading volume (8.1 M) remained 1.9 million below its 50-day average volume of 10.0 M.

The American Based biotech company has Increased the 2021 supply forecast to between 800 million and 1 billion doses. It also made additional investments to increase the global supply for COVID-19 Vaccine to up to 3 billion doses in 2022. The Company announced data supporting 3-month refrigerated stable formulation.

New data of Moderna Inc shows a single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two variants of concern in vaccinated clinical trial participants. Initial analysis of Phase 2/3 TeenCOVE study of mRNA-1273 in adolescents ages 12 to 17 years showed vaccine efficacy against COVID-19 of 96%; mRNA-1273 was generally well tolerated with no serious safety concerns identified to date. Phase 3 study of mRNA-1273 in adults with a kidney or liver transplant is ongoing. The company plans to launch rolling submission for BLA in the U.S. this month

Be First to Comment

Leave a Reply

Your email address will not be published.